Press Releases

Press Releases

  1. BTG plc: Appointment of Non-executive Director

  2. BTG plc: Annual General Meeting

  3. Varithena® Earns FDA Approval for 30 Day Post-Activation Shelf Life

  4. BTG completes the acquisition of Galil Medical

  5. BTG Joins Global Liver Institute Partnership Network to Transform Care for Liver Cancer Patients

  6. New study highlights potential cost savings when using yttrium-90 glass microspheres for treatment of hepatocellular carcinoma

  7. BTG plc: Final Results 2016

  8. BTG plc acquires Galil Medical, a leader in cryoablation

  9. BTG plc: Close Period Update

  10. BTG to Initiate Multi-Centre TARGET Study Evaluating Dosimetry for 90Y Radioembolisation Therapy in Patients With Hepatocellular Carcinoma

  11. BTG announces US launch of LC Bead LUMI™, ground-breaking radiopaque embolic bead

  12. BTG International Canada Expands Operations To Directly Sell Interventional Oncology Products

  13. New Data from Largest Prospective Study on CroFab® for Treatment of Copperhead Snake Envenomation

  14. First Patient Treated With LC Bead LUMI™ Radiopaque Embolic Bead Supported by Philips Live Image Guidance

  15. First Patients in South Korea Receive TheraSphere® Radioembolisation Treatment

  16. BTG Announces Presentation of New Vistogard® (uridine triacetate) Data at American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI)